BioSyent Inc. RX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 41.13% | 5.74% | 23.98% | 15.09% | 26.31% |
| Total Depreciation and Amortization | 391.02% | 140.31% | 12.93% | 115.17% | 72.70% |
| Total Amortization of Deferred Charges | -- | -- | -87.86% | -- | -- |
| Total Other Non-Cash Items | 833.33% | -352.87% | -63.58% | 35.20% | 67.50% |
| Change in Net Operating Assets | -223.85% | 98.14% | 147.96% | -101.47% | 140.04% |
| Cash from Operations | -27.24% | 496.28% | 33.78% | -58.46% | 327.29% |
| Capital Expenditure | 8.89% | -44.60% | -55.56% | 200.00% | -125.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 379.87% | 171.69% | 170.70% | 108.63% | -97.37% |
| Cash from Investing | 422.16% | -1,971.91% | 171.79% | 108.86% | -97.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4,362.71% | -8,507.16% | -11.16% | -7.39% | -5.26% |
| Issuance of Common Stock | 2,166.67% | -56.92% | -100.00% | -31.47% | -83.42% |
| Repurchase of Common Stock | -7,302.13% | -96.97% | 99.67% | 26.32% | 93.64% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -10.84% | -15.06% | -10.23% | -6.93% | -6.77% |
| Other Financing Activities | -24.60% | 3.05% | 17.86% | 17.12% | 16.00% |
| Cash from Financing | -583.22% | 197.84% | 84.73% | -8.36% | 30.63% |
| Foreign Exchange rate Adjustments | 68.00% | 5,820.00% | -139.91% | 126.98% | -2,600.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -131.95% | -1,266.23% | 885.54% | 164.14% | -37.45% |